Overview

Study Evaluating the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

Status:
Completed
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences